DCP
RPRX icon

Davern Capital Partners’s Royalty Pharma RPRX Stock Holding History

Davern Capital Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.8M Buy
1,155,809
+635,800
+122% +$33.1M 11.05% 3
2026
Q1 		$24.9M Sell
520,009
-320,641
-38% -$14M 6.84% 9
2025
Q4 		$32.5M Buy
+840,650
New +$32.1M 10.5% 4

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Davern Capital Partners's RPRX Position: Q2 2026 in Review

Davern Capital Partners increased its Royalty Pharma (RPRX) stake by 122% in Q2 2026, buying an estimated $33.1M and bringing the position to 1,155,809 shares worth $64.8M. The position accounts for 11.05% of the portfolio, ranked #3.

Davern Capital Partners first reported a position in RPRX in Q4 2025 and has held it in 3 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Davern Capital Partners held 1,155,809 shares of Royalty Pharma worth $64.8M as of Q2 2026.
  • Davern Capital Partners bought 635,800 Royalty Pharma shares in Q2 2026, an estimated $33.1M.
  • Royalty Pharma made up 11.05% of Davern Capital Partners's portfolio in Q2 2026, its #3 holding.
  • Davern Capital Partners first reported a position in Royalty Pharma in Q4 2025 and has held it in 3 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Davern Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.